Article information
Full text is only aviable in PDF
REFERENCES
[1]
MA Woodhead, JT Macfarlane, JS McCracken, DH Rose, RG Finch.
Prospective study of the aetiology and outcome of pneumonia in the community.
Lancet, 1 (1987), pp. 671-674
[2]
C Jokinen, L Heiskanen, H Juvonen, S Kallinen, K Karkola, M Kporpi, et al.
Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland.
Am J Epidemiol, 137 (1993), pp. 977-988
[3]
J Almirall, I Bolíbar, J Vidal, G Sauca, P Coll, B Niklason, B Bartolomé.
Epidemiology of community acquired pneumonia in adults: a population-based study.
Eur Respir J, 15 (2000), pp. 757-763
[4]
C Santos de Unamuno, MA Llorente, E Carandell, M Gutiérrez, J Riera, A Ramírez, et al.
Lugar de atención, etiología, y tratamiento de las neumonías adquiridas en la comunidad de Palma de Mallorca.
Med Clin (Barc), 110 (1998), pp. 290-294
[5]
M Murrie, J Hueto.
Epidemiología de las neumonías adquiridas en la comunidad en el Área de Salud I de Navarra.
Med Clin (Barc), 97 (1991), pp. 50-52
[6]
MJ Fine, MA Smith, CA Carson, SS Mutha, SS Sankey, LA Weissfeld, et al.
Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis.
JAMA, 275 (1996), pp. 134-141
[7]
M Woodhead.
Community-acquired pneumonia in Europe: causative pathogens and resistance patterns.
Eur Respir J, 20 (2002), pp. 20-27
[8]
FJ Álvarez, D del Castillo, A García Fernández, B Romero, J del Rey, G Soto, J Castillo.
Estudio prospectivo de 221 neumonías adquiridas en la comunidad seguidas de forma ambulatoria. Etiología y evolución clínico-radiológica.
Med Clin (Barc), 116 (2001), pp. 161-166
[9]
R Zalacaín, N Talayero, V Achótegui, J Corral, I Barreña, V Sobradillo.
Neumonía adquirida en la comunidad. Fiabilidad de los criterios clínicos para decidir tratamiento ambulatorio.
Arch Bronconeumol, 33 (1997), pp. 74-79
[10]
M Falguera, O Sacristán, A Nogués, A Ruiz, M García, A Manonelles, M Rubio-Caballero.
Non severe community pneumonia: correlation between cause and severity or comorbidity.
Arch Int Med, 161 (2001), pp. 1866-1872
[11]
J Blanquer, R Blanquer, R Borrás, D Nauffal, P Morales, R Menéndez, et al.
Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.
Thorax, 46 (1991), pp. 508-511
[12]
L Molinos, R Fernández, JA Gullón, G Rubinos, MA Alonso, C Escudero, et al.
Neumonía adquirida en la comunidad con tratamiento hospitalario. Interés de la clínica y exámenes complementarios en la predicción de la etiología.
Arch Bronconeumol, 33 (1997), pp. 230-235
[13]
M Ruiz, S Ewig, MA Marcos, JA Martínez, F Arancibia, J Mensa, A Torres.
Etiology of community-acquired pneumonia: impact of age, comorbidity and severity.
Am J Respir Crit Care Med, 160 (1999), pp. 397-405
[14]
N Sopena, M Sabriá, ML Pedro-Botet, JM Manterola, L Matas, J Domínguez, et al.
Prospective study of community-acquired pneumonia of bacterial etiology in adults.
Eur J Clin Microbiol Infect Dis, 18 (1999), pp. 852-858
[15]
B Rosón, J Carratalá, J Dorca, A Casanova, F Manresa, F Gudiol.
Etiology, reasons for hospitalization, risk classes and outcomes of community acquired pneumonia in patients hospitalised on the basis of conventional admission criteria.
Clin Infect Dis, 33 (2001), pp. 158-165
[16]
R Menéndez, J Córdoba, P de la Cuadra, MJ Cremades, JL Lope Hontagas, M Salavert, et al.
Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community acquired pneumonia.
Am J Respir Crit Care Med, 159 (1999), pp. 1868-1873
[17]
A Ruiz-González, M Falguera, A Nogués, M Rubio Caballero.
Is Streptococcus pneumoniae the leading cause of pneumonia of unknown aetiology? A microbiologic study of lung aspirates in consecutive patients with community acquired pneumonia.
Am J Med, 106 (1999), pp. 385-390
[18]
B Rosón, N Fernández-Sabé, J Carratalá, R Verdaguer, J Dorca, F Manresa, et al.
Contribution of a urinary antigen assay (Binax Now) to the early diagnosis of pneumococcal pneumonia.
Clin Infect Dis, 38 (2004), pp. 222-226
[19]
A de Roux, MA Marcos, E García, J Mensa, S Ewig, H Lode, et al.
Viral community-acquired pneumonia in nonimmunocompromised adults.
Chest, 125 (2004), pp. 1343-1352
[20]
J Pachón, MD Prado, F Capote, JA Cuello, J Garnacho, A Verano.
Severe community-acquired pneumonia. Etiology, prognosis and treatment.
Am Rev Respir Dis, 142 (1990), pp. 369-373
[21]
A Torres, J Serra-Batllés, A Ferrer, P Jiménez, R Celis, E Cobo, et al.
Severe community acquired pneumonia. Epidemiology and prognostic factors.
Am Rev Respir Dis, 114 (1991), pp. 312-318
[22]
J Rello, A Quintana, V Ausina, A Net, G Prats.
A three-year study of severe community acquired pneumonia with emphasis on outcome.
Chest, 103 (1993), pp. 232-235
[23]
O Leroy, C Santré, C Beuscart, H Georges, B Guery, JM Jacquier, et al.
A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit.
Intensive Care Med, 21 (1995), pp. 24-31
[24]
J Rello, R Rodríguez, P Jubert, B Álvarez, the study group on severe community acquired pneumonia.
Severe community acquired pneumonia in the elderly: epidemiology and prognosis.
Clin Infect Dis, 23 (1996), pp. 723-728
[25]
J Rello, M Bodí, M Navarro, E Díaz, M Gallego, J Vallés.
Microbiological testing and outcome of patients with severe community-acquired pneumonia.
Chest, 123 (2003), pp. 174-180
[26]
R Zalacaín, A Torres, R Celis, J Blanquer, J Aspa, L Esteban, et al.
on behalf of “Pneumonia in the elderly” working group. Area TIR. Community-acquired pneumonia in the elderly: Spanish multicentre study.
Eur Respir J, 21 (2003), pp. 294-302
[27]
N Fernández-Sabé, J Carratalá, B Rosón, J Dorca, R Verdaguer, F Manresa, et al.
Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes.
Medicine, 82 (2003), pp. 159-169
[28]
AA el Solh, AT Aquiline, RS Dhillon, F Ramadan.
Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia.
Am J Respir Crit Care Med, 166 (2002), pp. 1038-1042
[29]
WS Lim, JT MacFarlane.
A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia.
Eur Respir J, 18 (2001), pp. 362-368
[30]
A Torres, J Dorca, R Zalacaín, S Bello, M el-Ebiary, L Molinos, et al.
Community acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study.
Am J Respir Crit Care Med, 154 (1996), pp. 1456-1461
[31]
F Arancibia, TT Bauer, S Ewig, J Mensa, J González, MS Niederman, et al.
Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk factors and prognosis.
Arch Intern Med, 162 (2002), pp. 1849-1858
[32]
TJ Marrie.
Bacteremic pneumococcal pneumonia: a continuously evolving disease.
J Infect, 24 (1992), pp. 247-255
[33]
DH Akbar.
Bacterial pneumonia: comparison between diabetics and non-diabetics.
Acta Diabetol, 38 (2001), pp. 77-82
[34]
M Ruiz, S Ewig, A Torres, F Arancibia, F Marco, J Mensa, et al.
Severe community-acquired pneumonia. Risk factors and follow-up epidemiology.
Am J Respir Crit Care Med, 160 (1999), pp. 923-929
[35]
PE Marik.
Aspiration pneumonitis and aspiration pneumonia.
N Eng J Med, 344 (2001), pp. 665-671
[36]
P Nuorti, J Butler, M Farley, L Harrison, A McGeer, M Kolczak, et al.
The active bacterial core surveillance team. Cigarette smoking and invasive pneumococcal disease.
N Engl J Med, 342 (2000), pp. 681-689
[37]
J Fernández, P López, D Orozco, J Merino.
Clinical study of an outbreak of Legionnaire's disease in Alcoy, Southeastern Spain.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 729-735
[38]
C Agustí, A Rañó, X Filella, J González, A Moreno, A Xaubet, et al.
Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment. Etiology, prognostic factors and associated inflammatory response.
Chest, 123 (2003), pp. 488-498
[39]
A García-Fulgueiras, C Navarro, D Fenoll, J García, P González-Diego, T Jiménez-Bunuelas, et al.
Legionnaires' disease outbreak in Murcia, Spain.
Emerg Infect Dis, 9 (2003), pp. 915-921
[40]
V Sobradillo, P Ansola, F Baranda, C Corral.
Q fever pneumonia: a review of 164 cases in the Basque Country.
Eur Respir J, 2 (1989), pp. 263-266
[41]
R Arnal, L Borderías, C Serón, A Zurutuza.
Etiología de la neumonía adquirida en la comunidad que requiere ingreso hospitalario en un período de 39 meses.
Arch Bronconeumol, 38 (2002), pp. 57
[42]
MS Niederman, LA Mandell, A Anzueto, JB Bass, WA Broughton, G Campbell, et al.
American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia.
Am J Respir Crit Care Med, 163 (2001), pp. 1730-1754
[43]
LA Mandell, JG Bartlett, SF Dowell, TM File Jr, DM Musher, C Whitney.
Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults.
Clin Infect Dis, 37 (2003), pp. 1405-1433
[44]
L Molinos, FJ López, V Faiña.
Neumonía adquirida en la comunidad.
Enfermedades respiratorias, pp. 333-340
[45]
J Dorca, S Bello, JM Blanquer, MR de Celis, L Molinos, A Torres, et al.
Diagnóstico y tratamiento de la neumonía adquirida en la comunidad.
Arch Bronconeumol, 33 (1997), pp. 240-246
[46]
CM Luna, J Ramírez, H López, JA Mazzei, JC Abreu de Oliveira, J Pereira, et al.
Grupo de trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre la neumonía adquirida de la comunidad.
Arch Bronconeumol, 37 (2001), pp. 340-348
[48]
JG Bartlett, SF Dowell, LA Mandell, TM File Jr, DM Musher, MJ Fine.
Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults.
Clin Infect Dis, 31 (2000), pp. 347-382
[49]
J MacFarlane, T Bosswell, G Douglas, R Finch, W Holmes, D Honeybourne, et al.
BTS guidelines for the management of community acquired pneumonia in adults.
Thorax, 56 (2001), pp. 1iv-64iv
[50]
JT MacFarlane, AC Miller, WH Roderick Smith, AH Morris, DH Rose.
Comparative radiographic features of community-acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis.
Thorax, 39 (1984), pp. 28-33
[51]
T Franquet.
Imaging of pneumonia: trends and algorithms.
Eur Respir J, 18 (2001), pp. 196-208
[52]
PB Hasley, MN Albaum, CR Fuhrman, CA Britton, TJ Marrie, DE Singer, et al.
Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?.
Arch Intern Med, 156 (1996), pp. 2206-2212
[53]
R Riquelme, A Torres, M el-Ebiary, JP de la Bellacasa, R Estruch, J Mensa, et al.
Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors.
Am J Crit Care Med, 154 (1996), pp. 450-455
[54]
SJ Skerrett.
Diagnostic testing to establish a microbial cause is helpful in the management of community-acquired pneumonia.
Semin Respir Infect, 12 (1997), pp. 308-321
[55]
F Arancibia, S Ewig, JA Martínez, M Ruiz, T Bauer, MA Marcos, et al.
Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.
Am J Respir Crit Care Med, 162 (2000), pp. 154-160
[56]
J Frias, M Gomis, J Prieto, J Mensa, E Bouza, JA García-Rodríguez, et al.
Tratamiento empírico inicial de la neumonía adquirida en la comunidad.
Rev Esp Quimioter, 11 (1998), pp. 255-261
[57]
G Huchon, M Woodhead, the ERS Task Force.
Guidelines for management of adult community-acquired lower respiratory tract infections.
Eur Respir J, 11 (1998), pp. 986-991
[58]
F Arancibia, S Ewig, J Martínez, M Ruiz, T Bauer, M Marcos, et al.
Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.
Am J Respir Crit Care Med, 162 (2000), pp. 154-160
[59]
B Rosón, J Carratalá, R Verdaguer, J Dorca, F Manresa, F Gudiol.
Prospective study of the uselfuness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization.
Clin Infect Dis, 31 (2000), pp. 869-874
[60]
E García-Vázquez, M Marcos, J Mensa, A de Roux, J Puig, C Font, et al.
Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system.
Arch Intern Med, 164 (2004), pp. 1807-1811
[61]
SG Campbell, TJ Marrie, R Anstey, S Ackroyd-Stolarz, G Dickinson.
Utility of blood cultures in the management of adults with community acquired pneumonia discharged from the emergency department.
Emerg Med J, 20 (2003), pp. 521-523
[62]
DE Craven.
Blood cultures for community-acquired pneumonia. Piecing together a mosaic for doing less.
Am J Respir Crit Care Med, 169 (2004), pp. 327-335
[63]
GW Waterer, RG Wunderink.
The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures.
Respir Med, 95 (2001), pp. 78-82
[64]
ML Metersky, A Ma, DW Bratzler, PM Houck.
Predicting bacteremia in patients with community-acquired pneumonia.
Am J Respir Crit Care Med, 169 (2004), pp. 342-347
[65]
M Marcos, M Jiménez de Anta, J de la Bellacasa, J González, E Martínez, E García, et al.
Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults.
Eur Respir J, 21 (2003), pp. 209-214
[66]
JJ Oosterheert, MJ Bonten, E Buskens, MM Schneider, IM Hoepelman.
Algorythm to determine cost savings of targeting antimicrobial therapy based on results of rapid diagnostic testing.
J Clin Microb, 41 (2003), pp. 4708-4713
[67]
J Roig, M Sabriá, ML Pedro-Botet.
Legionella sp.: community-acquired and nosocomial infection.
Curr Opin Infect Dis, 16 (2003), pp. 145-151
[68]
J Domínguez, S Blanco, C Prat, R Rivelo, MD Sánchez, MA Pallarés, et al.
Rapid centrifugal method for Legionella antigen concentration in urine samples.
Clin Microbiol Infect, 10 (2004), pp. 455
[69]
B Rosón, J Carratalá, N Fernández-Sabé, F Tubau, F Manresa, F Gudiol.
Causes and factors associated with early failure in hospitalized patients with community acquired pneumonia.
Arch Intern Med, 164 (2004), pp. 502-508
[70]
S Bello, E Chacón, A Hernández.
Técnicas no invasivas en el diagnóstico de las neumonías.
Arch Bronconeumol, 34 (1998), pp. 31-40
[71]
J Roig, X Soler, C Domingo, G de Celis.
Serological evidence of Legionella species infection in acute exacerbation of COPD.
Eur Respir J, 20 (2002), pp. 504-505
[72]
J Domínguez, N Gali, L Matas, P Pedroso, S Blanco, M Jiménez, et al.
PCR detection of Streptococcus pneumoniae DNA in serum samples for pneumococcal pneumonia diagnosis.
Clin Microbiol Infect, 7 (2001), pp. 164-166
[73]
J Macfarlane, W Holmes, P Gard, R Macfarlane, D Rose, V Weston, et al.
Prospective study of the incidence, aetiology and outcome of lower respiratory tract illness in the community.
Thorax, 56 (2001), pp. 109-114
[74]
A García, B Rosón, JL Pérez, R Verdaguer, J Dorca, J Carratalá, et al.
Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumococcal pneumonia.
J Clin Microbiol, 37 (1999), pp. 709-714
[75]
A Ruiz-González, A Nogués, M Falguera, JM Porcel, E Huelin, M Rubio-Caballero.
Rapid detection of pneumococcal antigen in lung aspirates: comparison with culture and PCR technique.
Respir Med, 91 (1997), pp. 201-206
[76]
P Jiménez, F Saldias, M Meneses, ME Silva, MG Wilson, L Otth.
Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia. Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures.
Chest, 103 (1993), pp. 1023-1027
[77]
E Prats, J Dorca, M Pujol, L García, B Barreiro, R Verdaguer, et al.
Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia.
Eur Respir J, 19 (2002), pp. 944-951
[78]
A Torres, N Fabregas, S Ewig, J Puig de la Bellacasa, T Bauer, J Ramírez.
Sampling methods for ventilator-associated pneumonia: validation using different histologic and microbiological references.
Crit Care Med, 28 (2000), pp. 2799-2804
[79]
JP Metlay, MJ Fine.
Testing strategies in the initial management of patients with community-acquired pneumonia.
Ann Intern Med, 138 (2003), pp. 109-118
[80]
AM Neill, IR Martin, R Weir, R Anderson, A Chereshsky, MJ Epton, et al.
Community acquired pneumonia: aetiology and usefulness of severity criteria on admission.
Thorax, 51 (1996), pp. 1010-1016
[81]
MJ Fine, TE Auble, DM Yealy, BH Hanusa, LA Weissfeld, DE Singer, et al.
A prediction rule to identify low-risk patients with community-acquired pneumonia.
N Engl J Med, 336 (1997), pp. 243-250
[82]
SJ Atlas, TI Benzer, LH Borowsky, Y Chang, DC Burnham, JP Metlay, et al.
Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.
Arch Intern Med, 158 (1998), pp. 1350-1356
[83]
TJ Marrie, CY Lau, SL Wheeler, CJ Wong, MK Vandervoort, BG Feagan.
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
JAMA, 283 (2000), pp. 749-755
[84]
FW Arnold, JA Ramírez, LC McDonald, EL Xia, PP España, A Capelastegui, et al.
Hospitalization for community-acquired pneumonia: the pneumonia severity index versus clinical judgment. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia.
Chest, 124 (2003), pp. 121-124
[85]
R Menéndez, MJ Cremades, E Martínez-Moragón, JJ Soler, S Reyes, M Perpiñá.
Duration of length of stay in pneumonia: influence of clinical factors and hospital type.
Eur Respir J, 22 (2003), pp. 643-648
[86]
PP España, A Capelastegui, JM Quintana, A Soto, I Gorordo, M García-Urbaneja, et al.
A prediction rule to identify allocation of inpatient care in community-acquired pneumonia.
Eur Respir J, 21 (2003), pp. 695-701
[87]
DC Angus, TJ Marrie, DS Obrosky, G Clermont, TT Dremsizov, C Coley, et al.
Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria.
Am J Respir Crit Care Med, 166 (2002), pp. 717-723
[88]
WS Lim, MM van der Eerden, R Laing, WG Boersma, N Karalus, GI Town, et al.
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.
Thorax, 58 (2003), pp. 377-382
[89]
S Ewig, T Kleinfeld, T Bauer, K Seifert, H Schafer, N Goke.
Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population.
Eur Respir J, 14 (1999), pp. 370-375
[90]
S Ewig, M Ruiz, J Mensa, MA Marcos, JA Martínez, F Arancibia, et al.
Severe community-acquired pneumonia. Assessment of severity criteria.
Am J Respir Crit Care Med, 158 (1998), pp. 1102-1108
[91]
A Kamath, MC Pasteur, MG Slade, BD Harrison.
Recognising severe pneumonia with simple clinical and biochemical measurements.
Clin Med, 3 (2003), pp. 54-56
[92]
S Ewig, A de Roux, T Bauer, E García, J Mensa, M Niederman, et al.
Validation of predictive rules and indices of severity for community acquired pneumonia.
Thorax, 59 (2004), pp. 421-427
[93]
EM Mortensen, CM Coley, DE Singer, TJ Marrie, DS Obrosky, WN Kapoor, et al.
Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study.
Arch Intern Med, 162 (2002), pp. 1059-1064
[94]
FE Pascual, MA Matthay, P Bacchetti, RM Wachter.
Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation.
Chest, 117 (2000), pp. 503-512
[95]
Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Sociedad Española de Quimioterapia (SEQ), Sociedad Española de Medicina Interna (SEMI) y Sociedad Española de Medicina de Urgencias y Emergencias (SEMES).
Tratamiento antibiótico empírico inicial de la neumonía adquirida en la comunidad en el paciente adulto inmunocompetente.
Rev Esp Quimioter, 16 (2003), pp. 457-466
[96]
J Aspa, O Rajas, F Rodríguez de Castro, J Blanquer, R Zalacaín, A Fenoll, et al.
Drug-resistant pneumococcal pneumonia: Clinical relevance and related factors.
Clin Infect Dis, 38 (2004), pp. 787-798
[97]
F Baquero, J García Rodríguez, J García de Lomas, L Aguilar.
Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results a multicenter surveillance study.
Antimicrob Agents Chemother, 43 (1999), pp. 357-359
[98]
C Urban, N Rahman, X Zhao, N Mariano, S Segal-Maurer, K Drlica, et al.
Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.
J Infect Dis, 184 (2001), pp. 794-798
[99]
P Ho, W Tse, K Tsang, T Kwok, T Ng, V Cheng, et al.
Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.
Clin Infect Dis, 32 (2001), pp. 701-707
[100]
R Davidson, R Cavalcanti, J Brunton, D Bast, J de Azavedo, P Kibsey, et al.
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med, 346 (2002), pp. 747-750
[101]
K Anderson, J Tan, T File Jr, J DiPersio, B Willey, D Low.
Emergence of levofloxacin-resistance pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Clin Infect Dis, 37 (2003), pp. 376-381
[102]
PM Houck, DW Bratzler, W Nsa, A Ma, JG Bartlett.
Timing of antibiotic administration and outcomes for medicare patients hospitalized with community-acquired pneumonia.
Arch Intern Med, 164 (2004), pp. 637-644
[103]
DS Battleman, M Callahan, HR Thaler.
Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization.
Arch Intern Med, 162 (2002), pp. 682-688
[104]
PP Gleason, TP Meehan, JM Fine, DH Galusha, MJ Fine.
Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
Arch Intern Med, 159 (1999), pp. 2562-2572
[105]
RB Brown, P Ianini, P Gross, M Kunkel.
Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of ahospital claims-made database.
Chest, 123 (2003), pp. 1503-1511
[106]
JA Martínez, P Horcajada, M Almela, F Marco, A Soriano, E García, et al.
Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.
Clin Infect Dis, 36 (2003), pp. 389-395
[107]
C Fogarty, G Siami, R Kohler.
Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults.
Clin Infect Dis, 38 (2004), pp. 16-23
[108]
F Álvarez-Lerma, M Palomar, P Olaechea, C León, B Sánchez Bermejo.
Estudio observacional sobre el uso de levofloxacino en pacientes ingresados en UCI.
Enferm Infecc Microbiol Clin, 22 (2004), pp. 220-226
[109]
R Finch, D Schurmann, O Collins, R Kubin, J McGivern, H Bobbaers, et al.
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Antimicrob Agents Chemother, 46 (2002), pp. 1746-1754
[110]
R Menéndez, A Torres, R Zalacaín, J Aspa, J Martín Villasclaras, L Borderías, et al.
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.
Thorax, 59 (2004), pp. 960-965
[111]
G Radberg, LE Nilsson, S Svensson.
Development of quinoloneimipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin.
Antimicrob Agents Chemother, 34 (1990), pp. 2142-2147
[112]
RE Siegel, NA Halpern, PL Almenoff, A Lee, R Cadhin, JG Greene.
A prospective randomized study of inpatient i.v. antibiotics for community-acquired pneumonia. The optimal duration of therapy.
Chest, 110 (1996), pp. 965-971
[113]
EA Halm, MJ Fine, TJ Marrie, CM Coley, WN Kapoor, DS Obrosky, et al.
Time to clinical stability in patients hospitalized with community-acquired pneumonia. Implications for practice guidelines.
JAMA, 279 (1998), pp. 1452-1457
[114]
R Menéndez, A Torres, F Rodríguez de Castro, R Zalacaín, J Aspa, J Martín Villasclaras, et al.
Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients.
Clin Infect Dis, 39 (2004), pp. 1783-1790
[115]
DC Rhew, GS Tu, J Ofman, JM Henning, MS Richards, SR Weingarten.
Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.
Arch Intern Med, 161 (2001), pp. 722-727
[116]
LM Dunbar, RG Wunderink, MP Habib, LG Smith, AM Tennenberg, MM Khashab, et al.
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Clin Infect Dis, 37 (2003), pp. 752-760
[117]
J Plouffe, DB Schwartz, A Kolokathis, BW Sherman, PM Arnow, PA Gezon, et al.
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia.
Antimicrob Agents Chemother, 44 (2000), pp. 1796-1802
[118]
LA Mandell, TM File.
Short-course treatment of community-acquired pneumonia.
Clin Infect Dis, 37 (2003), pp. 761-763
[119]
M Confalonieri, A Potena, G Carbone, RD Porta, EA Tolley, G Meduri.
Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation.
Am J Respir Crit Care Med, 160 (1999), pp. 1585-1591
[120]
P Jolliet, B Abajo, P Pasquina, JC Chevrolet.
Non-invasive pressure support ventilation in severe community-acquired pneumonia.
Intensive Care Med, 27 (2001), pp. 812-821
[121]
M Ferrer, A Esquinas, M León, G González, A Alarcón, A Torres.
Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial.
Am J Respir Crit Care Med, 168 (2003), pp. 1438-1444
[122]
SV Baudouin.
The pulmonary physician in critical care. 3: Critical care management of community acquired pneumonia.
Thorax, 57 (2002), pp. 267-271
[123]
F Rodríguez de Castro.
Bronquitis aguda. Neumonía extrahospitalaria.
Medicina Interna, 15th ed., pp. 792-799
[124]
R Menéndez, M Perpiñá, A Torres.
Evaluation of nonresolving and progressive pneumonia.
Semin Respir Infect, 18 (2003), pp. 103-111
[125]
Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR, 46 (1997), pp. 1-24
[126]
DS Fedson, MP Harward, RA Reid, DL Kaiser.
Hospital-based pneumococcal immunization: epidemiologic rationale from the Shenandoah study.
JAMA, 264 (1990), pp. 1117-1122
[127]
DS Fedson.
Improving the use of pneumococcal vaccine through a strategy of hospital-based immunization: a review of its rationale and implications.
J Am Geriatr Soc, 33 (1985), pp. 142-150
[128]
DS Fedson, A Wajda, P Nicol, GW Hammond, DL Kaiser, LL Roos.
Clinical effectiveness of influenza vaccination in Manitoba.
JAMA, 270 (1993), pp. 1956-1961
[129]
KL Nichol, KL Margolis, J Wuorenma, T von Sternberg.
The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community.
N Engl J Med, 331 (1994), pp. 778-784
[130]
SA Harper, K Fukuda, TM Uyeki, NJ Cox, CB Bridges.
Prevention and control of influenza recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR, 53 (2004), pp. 1-40
[131]
KL Margolis, KI Nichol, GA Poland, RE Pluhar.
Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial.
JAMA, 264 (1990), pp. 1139-1141
[132]
JE Kaplan, P Katona, ES Hurwitz, LB Schonberger.
Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981: lack of an association with influenza vaccination.
JAMA, 248 (1982), pp. 698-700
[133]
JH Harger, JM Ernst, GR Thurnau, A Moawad, V Momirova, MB Landon, et al.
Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women.
J Infect Dis, 185 (2002), pp. 422-427
I. Alfageme, J. Aspa, S. Bello,a J. Blanquer,*b R. Blanquer, L. Borderías, C. Bravo, R. de Celis, X. de Gracia, J. Dorca,c J. Gallardo, M. Gallego, R. Menéndez,a L. Molinos,a C. Paredes, O. Rajas, J. Rello, F. Rodríguez de Castro,b J. Roig, F. Sánchez-Gascón, A. Torres,c and R. Zalacaína
Section Coordinators
Special content about COVID-19
- Clinical characteristics and 2-year outcomes of chronic obstructive pulmonary disease patients with high blood eosinophil counts: a population-based prospective cohort study in China
- Hypersensitivity Pneumonitis-like Histological Findings Secondary to SARS-COV-2 Pneumonia
- Determinants of COVID-19 Hospitalization Costs in a Referral Hospital for Respiratory Diseases
- Multidisciplinary Consensus on the Management of Non-Invasive Respiratory Support in the COVID-19 Patient
Recommended
articles
articles
Arch Bronconeumol. 2020;56:792-800
Arch Bronconeumol. 2021;57 Supl 2:62-3
Arch Bronconeumol. 2021;57 Supl 1:47-54
Publish in
Archivos de Bronconeumología
Free access articles
Arch Bronconeumol. 2024;60:226-37
Arch Bronconeumol. 2024;60:iii-iv
Arch Bronconeumol. 2024;60:i
Graphical abstract
Archivos de Bronconeumología is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.
www.publicationethics.org.
Archivos de Bronconeumología follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals
Archivos de Bronconeumología
- Home
- All contents
- Publish your article
- About the journal
- Metrics
Article options